Page last updated: 2024-09-05

technetium tc 99m pentetate and Neuroendocrine Tumors

technetium tc 99m pentetate has been researched along with Neuroendocrine Tumors in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahmadzadehfar, H; Biersack, HJ; Ezziddin, K; Ezziddin, S; Haslerud, T; Nagarajah, J; Pape, UF; Reichman, K; Sabet, A	1

Other Studies

1 other study(ies) available for technetium tc 99m pentetate and Neuroendocrine Tumors

Article	Year
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Renal Insufficiency; Technetium Tc 99m Pentetate	2014

Article

Year

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.

European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:3

Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Renal Insufficiency; Technetium Tc 99m Pentetate

2014